QUINAPRIL REDUCES MICROALBUMINURIA IN ESSENTIAL HYPERTENSIVE AND IN DIABETIC HYPERTENSIVE SUBJECTS

被引：16

作者：

DOMINGUEZ, LJ

BARBAGALLO, M

KATTAH, W

GARCIA, D

SOWERS, JR

机构：

[1] Servicio de Endocrinologla, Hospital de San José, Bogota

[2] Division of Endocrinology and Hypertension, Wayne State University, Detroit, MI

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 08期

关键词：

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; QUINAPRIL; HYPERTENSION; DIABETES; INSULIN RESISTANCE; MICROALBUMINURIA;

D O I：

10.1016/0895-7061(95)00143-D

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

To investigate the metabolic and renal effects of the nonsulfhydryl, tissue-active ACE inhibitor quinapril in diabetes and in hypertension, we studied 30 essential hypertensives and 24 non-insulin-dependent (type II) diabetic (NIDDM) subjects with hypertension. Systolic and diastolic blood pressures, plasma glucose, and insulin responses to an oral glucose load (75 g), lipid profile, and urinary albumin excretion were evaluated before and after 8 weeks' administration of quinapril (10 to 40 mg/day). Quinapril produced a significant and comparable reduction of arterial blood pressure in both groups. Mean arterial pressure decreased from 114.8 +/- 0.9 to 94.2 +/- 1.1 (-17.9 +/- 1.5%) in the essential hypertensive group and from 118.4 +/- 1.6 to 96.2 +/- 1.4 (-18.4 +/- 1.6%) in the diabetic hypertensive group. In both essential hypertensives and diabetic-hypertensive subjects with microalbuminuria, quinapril significantly and comparably reduced the urinary albumin excretion rate (UAE); UAE decreased from 32.5 +/- 5.5 mu g/min to 14.7 +/- 3.7 mu g/min min (P < .05 v baseline) in the diabetic-hypertensive group and from 27.5 +/- 3.0 mu g/min to 11.6 +/- 2.7 mu g/min (P < .05 v baseline) in the essential hypertensives. Altogether, a direct correlation was found between the initial level of UAE and the UAE reduction after quinapril (Delta UAE) (r = 0.706, p < .05). Insulin and glucose responses to an oral glucose tolerance test and the lipid profiles were not modified by quinapril treatment. The results confirm that quinapril is an effective antihypertensive agent that additionally reduces microalbuminuria in both hypertensive diabetics and in patients with essential hypertension, without altering insulin sensitivity and lipid profiles.

引用

页码：808 / 814

页数：7

共 39 条

[31] Romanelli, Giustina, Bossoni, Et al., Short term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early stage nephropathy, Diabetes, 39, pp. 1333-1338, (1990)
[32] Garcia, Rennke, Brenner, Anderson, Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation, J Clin Invest, 80, pp. 867-874, (1987)
[33] Morelli, Loon, Meyer, Et al., Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy, Diabetes, 39, pp. 2-8, (1990)
[34] Berne, Pollare, Lithell, Effect of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors, Diabetes Care, 11, pp. 39-47, (1991)
[35] Whitcroft, Thomas, Rawthorne, Et al., Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics, Horm Metab Res, 22, pp. 42-44, (1990)
[36] Paolisso, Gambardella, Verza, Et al., ACE inhibition improves insulin-sensitivity in aged insulin resistant hypertensive patients, J Hum Hypertens, 6, pp. 175-179, (1992)
[37] Leblanc, Thote, Billault, Absence of effect of enalapril on the glycemic control and peripheral sensitivity to insulin in 10 diabetics patients treated with subcutaneous infusion of insulin, Presse Med, 17, pp. 2277-2280, (1988)
[38] Ludvik, Kueenburg, Brunnbauer, Et al., The effect of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension, J Cardiovasc Pharmacol, 18, pp. S157-S159, (1991)
[39] Donnelly, Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes and heart failure, J Cardiovasc Pharmacol, 20, pp. S38-S44, (1992)

← 1 2 3 4 →